C. Bejot

发表

Reduced‐dose fludarabine, cyclophosphamide, and rituximab (FCR‐Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia

D. Porter, K. Foon, S. Schuster, 2015, American journal of hematology.

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma

A. Goy, A. Mato, A. Pecora, 2014, British journal of haematology.

Targeting indolent non-Hodgkin lymphoma

A. Goy, T. Feldman, L. Leslie, 2017, Expert review of hematology.

The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVAD) alternating with rituximab-methotrexate-AraC (R-MTX-AraC).

A. Goy, A. Mato, A. Pecora, 2010 .